(Q45856337)

English

In vitro and clinical characterisation of a newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients

scientific article published on January 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/1829908

In vitro and clinical characterisation of a newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients (English)

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

colorectal cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Newcastle disease

1 reference

based on heuristic

inferred from title

Newcastle disease virus

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1829908

4 December 2022

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

author name string

W. Liebrich

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1829908

4 December 2022

P. Schlag

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1829908

4 December 2022

M. Manasterski

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1829908

4 December 2022

B. Lehner

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1829908

4 December 2022

M. Stöhr

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1829908

4 December 2022

P. Möller

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1829908

4 December 2022

V. Schirrmacher

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1829908

4 December 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1829908

4 December 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/1829908

full work available at URL

https://api.elsevier.com/content/article/PII:027753799190170I?httpAccept=text/xml

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

https://api.elsevier.com/content/article/PII:027753799190170I?httpAccept=text/plain

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/1829908

27

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/1829908

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/1829908

703-710

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/1829908

Virus-augmented tumor transplantation antigens: evidence for a Helper antigen mechanism

3

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate

5

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Viral Xenogenization of Intact Tumor Cells

6

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity

10

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response

11

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Invasion & Metastasis

12

9

117

author name string

Hoegen

publication date

1989

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

A rapid and simple procedure for dissociation of tumor tissue from the human colon

14

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects

15

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Newcastle disease virus pathotypes

16

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

CD30(Ki-1) antigen expression in a subset of gastric mucosal plasma cells and in a primary gastric plasmacytoma

17

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues

18

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis

19

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

A low-viscosity epoxy resin embedding medium for electron microscopy

21

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Incorporation studies of nucleic acid precursors in gastric cancer: an attempt in individualized chemotherapy

23

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Active-specific immunotherapy for melanoma

25

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial

28

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Ethylchlorformate polymerized tumor protein immunotherapy of the murine bladder tumor

29

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine

30

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

A new approach in specific, active immunotherapy

31

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract

32

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. 1. The role of tissue antigen, nonspecific reactions of nuclear material, and bacterial antigen as a cause for this phenomenon

33

1 reference

10.1016/0277-5379(91)90170-I

https://api.crossref.org/works/10.1016/0277-5379(91)90170-I

4 December 2022

Identifiers

10.1016/0277-5379(91)90170-I

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/1829908

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/1829908

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45856337&oldid=1784246164"